Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years. - Wikidata - awgldk - TriplyDB

Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years.

Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years.

http://www.wikidata.org/entity/Q37649687

about

Control of B lymphocyte development and functions by the mTOR signaling pathways.T cells and autoimmune kidney disease.Immunometabolism in systemic lupus erythematosus.Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective.Metabolic abnormalities and oxidative stress in lupus.Review: Metabolic Control of Immune System Activation in Rheumatic Diseases.Therapeutic potency of mTOR signaling pharmacological inhibitors in the treatment of proinflammatory diseases, current status, and perspectives.The Potential Role of Trained Immunity in Autoimmune and Autoinflammatory Disorders.Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus.

P2860

Q38674507-0C326B02-0424-421C-9068-41263D203D90 Q39175811-7D8D8F36-7FFF-4C10-8944-4D6D3CEA2B44 Q39209701-12F29852-FA42-431A-9F90-7C3A6808630D Q39379152-AEA68B7B-5C5A-4DFF-8205-196B37A14647 Q39390654-752E452F-B363-4C35-A795-2AFB1B335DCB Q47133379-580ED3E7-DF89-4AC1-8ED3-454273683B08 Q47573911-26A75C06-3798-4C52-91F1-3C96F171F098 Q50531937-B281D57C-1F7F-49B7-8179-81C7C73E98AE Q52650139-54619C66-73DD-4F7C-B2B1-9FB4A5F62252 Q55163735-AD3D5093-F114-43A1-8527-5F8657BCFF4E

P2860

Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years.

http://www.wikidata.org/entity/Q37649687

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Activation of the Mechanistic ...... idence in the Last Five Years.

@en

Activation of the Mechanistic ...... idence in the Last Five Years.

@nl

type

label

Activation of the Mechanistic ...... idence in the Last Five Years.

@en

Activation of the Mechanistic ...... idence in the Last Five Years.

@nl

prefLabel

Activation of the Mechanistic ...... idence in the Last Five Years.

@en

Activation of the Mechanistic ...... idence in the Last Five Years.

@nl

P1433

Q37649687-5D459FEF-1F42-48E0-989E-B6CA6216F83F

P1476

Q37649687-E3DA428F-7F58-4E7D-AEA5-19AA455B5748

P2093

Q37649687-318DF6E5-4094-4915-9845-72232EC18B55

Q37649687-31AA6783-2871-4A35-BDA4-C9487A2E0A8C

Q37649687-CCD15280-D07F-4968-9A83-AA67E19887A8

Q37649687-FE6B9A10-FC5C-4032-AD72-14284BAD5130

P2860

Q37649687-02C426A0-8A09-48E6-B525-481444567437

Q37649687-033E67A3-475A-41BD-A808-94139C99D94F

Q37649687-0A3D5922-98A7-4892-A550-312F59B28CEB

Q37649687-0E5EDE64-6EF5-454A-A103-A74CC6D3F9E3

Q37649687-0F323892-848D-4D86-87EF-FAD7EFDDC2EB

Q37649687-10347DA2-D43B-466B-AF83-48AE15B5EDB7

Q37649687-115A5771-F07A-4BA1-95CD-0BBE3FA493CD

Q37649687-1E6B2073-04DD-4C94-AD32-8F85B6F555BA

Q37649687-275F2D9A-9DEA-4350-A9E9-5F3E244F969F

Q37649687-2D679C99-58E0-42B0-A584-54AEE961BBC5

P2888

Q37649687-7D837FDE-52B0-4FC0-8528-C9720D1D5073

P304

Q37649687-72C71CBF-12E3-475C-A790-76F39FC35D87

P31

Q37649687-148EA8DA-6C13-4D60-8256-2C1E480A4674

P356

Q37649687-C2A33B5F-96C8-4ECA-91A5-C0A6BA115692

P433

Q37649687-0FC4CD8B-68FA-45F5-8E90-C1BC908C78B8

P478

Q37649687-761586E8-56A7-400B-97D6-D2B2CC5D6398

P50

Q37649687-1E85FB6C-A8ED-4BB7-B7F5-C05556D0D16D

P577

Q37649687-361DF233-E520-4C43-ADED-40800B222D75

P698

Q37649687-7F7EBAE0-ED83-4980-BE78-F8E157A87606

P932

Q37649687-3490C7B3-0EF0-4819-A3A1-02C6155874B5

P356

S11926-016-0622-8

P1433

Current Rheumatology Reports

P1476

Activation of the Mechanistic ...... idence in the Last Five Years.

@en

P2093

Katalin Banki

http://www.w3.org/2001/XMLSchema#string

Nick Huang

http://www.w3.org/2001/XMLSchema#string

Thomas Winans

http://www.w3.org/2001/XMLSchema#string

Zachary Oaks

http://www.w3.org/2001/XMLSchema#string

P2860

Disturbed T Cell Signaling and Altered Th17 and Regulatory T Cell Subsets in the Pathogenesis of Systemic Lupus Erythematosus

mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging

Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase

Liver injury correlates with biomarkers of autoimmunity and disease activity and represents an organ system involvement in patients with systemic lupus erythematosus.

Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL-10 signaling in patients with systemic lupus erythematosus.

Low abundance of the matrix arm of complex I in mitochondria predicts longevity in mice.

Tuberous sclerosis and fulminant lupus in a young woman.

Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus.

P2888

s11926-016-0622-8

P304

73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11926-016-0622-8

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27812954

http://www.w3.org/2001/XMLSchema#string

P932

5314949

http://www.w3.org/2001/XMLSchema#string